Literature DB >> 25410047

When compliance is an issue-how to enhance statin adherence and address adverse effects.

Kim Birtcher1.   

Abstract

Cardiovascular disease is prevalent and costly. Interventions and therapies that reduce morbidity and mortality associated with cardiovascular disease could have an enormous impact on clinical and economic outcomes. Statins reduce atherosclerotic cardiovascular disease-related morbidity and mortality; however, adherence to statins is less than optimal. It is important for clinicians as well as health plan managers to be aware of the patient- and insurance plan-specific factors that have been shown to influence adherence. Perceived statin-related side effects may also decrease adherence. Statin-related myalgia may be difficult to distinguish from myalgia caused by other conditions, and statin therapy may be discontinued unnecessarily in patients who would otherwise benefit. It is imperative that clinicians work closely with patients to improve adherence to statin therapy and be knowledgable in managing potential statin-related side effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25410047     DOI: 10.1007/s11883-014-0471-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  44 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  Impact of statin copayments on adherence and medical care utilization and expenditures.

Authors:  Teresa B Gibson; Tami L Mark; Kirsten Axelsen; Onur Baser; Dale A Rublee; Kimberly A McGuigan
Journal:  Am J Manag Care       Date:  2006-12       Impact factor: 2.229

3.  The demand for statin: the effect of copay on utilization and compliance.

Authors:  Patrick Thiebaud; Bimal V Patel; Michael B Nichol
Journal:  Health Econ       Date:  2008-01       Impact factor: 3.046

4.  Impact of adherence to statins on coronary artery disease in primary prevention.

Authors:  Marie-Hélène Bouchard; Alice Dragomir; Lucie Blais; Anick Bérard; Danielle Pilon; Sylvie Perreault
Journal:  Br J Clin Pharmacol       Date:  2007-01-03       Impact factor: 4.335

5.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

Review 6.  Predictors of nonadherence to statins: a systematic review and meta-analysis.

Authors:  Devin M Mann; Mark Woodward; Paul Muntner; Louise Falzon; Ian Kronish
Journal:  Ann Pharmacother       Date:  2010-08-11       Impact factor: 3.154

7.  Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

Authors:  Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

8.  Primary nonadherence to statin medications in a managed care organization.

Authors:  T Craig Cheetham; Fang Niu; Kelley Green; Ronald D Scott; Stephen F Derose; Southida S Vansomphone; Janet Shin; Kaan Tunceli; Kristi Reynolds
Journal:  J Manag Care Pharm       Date:  2013-06

9.  Adherence to statins in primary prevention: yearly adherence changes and outcomes.

Authors:  Julia F Slejko; Michael Ho; Heather D Anderson; Kavita V Nair; Patrick W Sullivan; Jonathan D Campbell
Journal:  J Manag Care Pharm       Date:  2014-01

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

View more
  9 in total

1.  Statins Lower Lipid Synthesis But Promote Secretion of Cholesterol-Enriched Extracellular Vesicles and Particles.

Authors:  Yundi Chen; Yongrui Xu; Jing Wang; Peter Prisinzano; Yuhao Yuan; Fake Lu; Mingfeng Zheng; Wenjun Mao; Yuan Wan
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Switching, Discontinuation, and Reinitiation of Statins Among Older Adults.

Authors:  Richard Ofori-Asenso; Jenni Ilomaki; Mark Tacey; Ella Zomer; Andrea J Curtis; Si Si; Andrew R Zullo; Maarit Jaana Korhonen; J Simon Bell; Sophia Zoungas; Danny Liew
Journal:  J Am Coll Cardiol       Date:  2018-11-27       Impact factor: 24.094

Review 3.  Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.

Authors:  Terrence L Trentman; Steven G Avey; Harish Ramakrishna
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Oct-Dec

4.  Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial.

Authors:  Sofa D Alfian; Rizky Abdulah; Petra Denig; Job F M van Boven; Eelko Hak
Journal:  BMJ Open       Date:  2020-01-06       Impact factor: 2.692

5.  Modifiable Factors Associated with Non-adherence to Antihypertensive or Antihyperlipidemic Drugs Are Dissimilar: a Multicenter Study Among Patients with Diabetes in Indonesia.

Authors:  Sofa D Alfian; Nurul Annisa; Fajriansyah Fajriansyah; Dyah A Perwitasari; Rizky Abdulah; Eelko Hak; Petra Denig
Journal:  J Gen Intern Med       Date:  2020-04-16       Impact factor: 5.128

6.  Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia.

Authors:  Nicole A Groth; Neil J Stone; Catherine P Benziger
Journal:  Clin Cardiol       Date:  2020-12-23       Impact factor: 2.882

7.  Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.

Authors:  Ji Yoon Kim; Jimi Choi; Sin Gon Kim; Nam Hoon Kim
Journal:  Cardiovasc Diabetol       Date:  2022-02-22       Impact factor: 9.951

8.  Statin Therapy for Preventing Recurrent Stroke in Patients with Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies.

Authors:  Yue Yin; Li Zhang; Iain Marshall; Charles Wolfe; Yanzhong Wang
Journal:  Neuroepidemiology       Date:  2022-06-26       Impact factor: 5.393

9.  Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.

Authors:  Peter P Toth; Craig Granowitz; Michael Hull; Amy Anderson; Sephy Philip
Journal:  Lipids Health Dis       Date:  2019-09-16       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.